DK2496580T3 - Benzodiazepinbromdomænehæmmer - Google Patents

Benzodiazepinbromdomænehæmmer

Info

Publication number: DK2496580T3
Authority: DK; Denmark
Prior art keywords: benzodiazepine; domain inhibitor; bromine domain; bromine; inhibitor
Prior art date: 2009-11-05

Application number

DK10740654.8T

Other languages

English (en)

Inventor

Romain Luc Marie Gosmini

Olivier Mirguet

Original Assignee

Glaxosmithkline Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-11-05

Filing date

2010-08-06

Publication date

2014-02-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42667965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2496580(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-11-05 Priority claimed from GB0919433A external-priority patent/GB0919433D0/en

2010-06-22 Priority claimed from GBGB1010509.6A external-priority patent/GB201010509D0/en

2010-08-06 Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc

2014-02-24 Application granted granted Critical

2014-02-24 Publication of DK2496580T3 publication Critical patent/DK2496580T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK10740654.8T 2009-11-05 2010-08-06 Benzodiazepinbromdomænehæmmer DK2496580T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0919433A GB0919433D0 (en)	2009-11-05	2009-11-05	Novel compounds
GBGB1010509.6A GB201010509D0 (en)	2010-06-22	2010-06-22	Novel compounds
PCT/EP2010/061518 WO2011054553A1 (en)	2009-11-05	2010-08-06	Benzodiazepine bromodomain inhibitor

Publications (1)

Publication Number	Publication Date
DK2496580T3 true DK2496580T3 (da)	2014-02-24

Family

ID=42667965

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK10740654.8T DK2496580T3 (da)	2009-11-05	2010-08-06	Benzodiazepinbromdomænehæmmer
DK13192666.9T DK2722334T3 (da)	2009-11-05	2010-08-06	Benzodiazepin bromdomæneinhibitor

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK13192666.9T DK2722334T3 (da)	2009-11-05	2010-08-06	Benzodiazepin bromdomæneinhibitor

Country Status (33)

Country	Link
US (3)	US9023842B2 (da)
EP (3)	EP2496580B1 (da)
JP (1)	JP5524343B2 (da)
KR (1)	KR101424989B1 (da)
CN (1)	CN102762569B (da)
AU (1)	AU2010314395B2 (da)
BR (1)	BR112012010706A2 (da)
CA (1)	CA2779355C (da)
CL (1)	CL2012001178A1 (da)
CO (1)	CO6540003A2 (da)
CR (1)	CR20120283A (da)
CY (2)	CY1114988T1 (da)
DK (2)	DK2496580T3 (da)
DO (1)	DOP2012000114A (da)
EA (1)	EA020390B1 (da)
ES (3)	ES2446647T3 (da)
HK (3)	HK1175458A1 (da)
HR (2)	HRP20140107T1 (da)
HU (1)	HUE026421T2 (da)
IL (2)	IL219090A0 (da)
MA (1)	MA33803B1 (da)
ME (1)	ME02360B (da)
MX (1)	MX2012005295A (da)
MY (1)	MY160456A (da)
NZ (1)	NZ599258A (da)
PE (1)	PE20121181A1 (da)
PH (1)	PH12012500894A1 (da)
PL (2)	PL2722334T3 (da)
PT (2)	PT2496580E (da)
RS (2)	RS53179B (da)
SI (2)	SI2722334T1 (da)
SM (2)	SMT201400024B (da)
WO (1)	WO2011054553A1 (da)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3050885B1 (en) *	2009-11-05	2017-10-18	GlaxoSmithKline LLC	Benzodiazepine bromodomain inhibitor
GB0919432D0 (en) *	2009-11-05	2009-12-23	Glaxosmithkline Llc	Use
CN103180318B (zh)	2010-05-14	2017-05-10	达那-法伯癌症研究所	雄性避孕组合物以及使用方法
EP2569434B1 (en)	2010-05-14	2019-09-04	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating leukemia and related disorders
WO2011143669A2 (en)	2010-05-14	2011-11-17	Dana-Farber Cancer Institute, Inc	Compositions and methods for treating neoplasia, inflammatory disease and other disorders
WO2012075456A1 (en)	2010-12-02	2012-06-07	Constellation Pharmaceuticals	Bromodomain inhibitors and uses thereof
AR084070A1 (es)	2010-12-02	2013-04-17	Constellation Pharmaceuticals Inc	Inhibidores del bromodominio y usos de los mismos
EP2705039B1 (en)	2011-05-04	2017-07-26	Constellation Pharmaceuticals, Inc.	Bromodomain inhibitors and uses thereof
WO2012174487A2 (en)	2011-06-17	2012-12-20	Constellation Pharmaceuticals, Inc.	Bromodomain inhibitors and uses thereof
WO2013027168A1 (en)	2011-08-22	2013-02-28	Pfizer Inc.	Novel heterocyclic compounds as bromodomain inhibitors
DE102011082013A1 (de)	2011-09-01	2013-03-07	Bayer Pharma AG	6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
WO2013097052A1 (en)	2011-12-30	2013-07-04	Abbott Laboratories	Bromodomain inhibitors
CN104334526A (zh)	2012-04-20	2015-02-04	艾伯维公司	异吲哚酮衍生物
TWI602820B (zh)	2012-06-06	2017-10-21	星宿藥物公司	溴域抑制劑及其用途
EP2864336B1 (en)	2012-06-06	2016-11-23	Constellation Pharmaceuticals, Inc.	Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
KR20150023722A (ko)	2012-06-12	2015-03-05	애브비 인코포레이티드	피리디논 및 피리다지논 유도체
MX2015001880A (es)	2012-08-16	2015-05-11	Bayer Pharma AG	2,3-benzodiacepinas.
BR112015002824A2 (pt) *	2012-08-16	2017-08-08	Glaxosmithkline Llc	composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
US9663523B2 (en)	2012-09-28	2017-05-30	Bayer Pharma Aktiengesellschaft	BET protein-inhibiting 5-aryltriazoleazepines
US9422290B2 (en)	2012-11-13	2016-08-23	Boehringer Ingelheim International Gmbh	Triazolopyridazine
US9266891B2 (en) *	2012-11-16	2016-02-23	Boehringer Ingelheim International Gmbh	Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
US9765039B2 (en)	2012-11-21	2017-09-19	Zenith Epigenetics Ltd.	Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en)	2012-11-21	2014-05-30	Rvx Therapeutics Inc.	Cyclic amines as bromodomain inhibitors
WO2014096965A2 (en)	2012-12-21	2014-06-26	Rvx Therapeutics Inc.	Novel heterocyclic compounds as bromodomain inhibitors
US9492460B2 (en) *	2013-02-27	2016-11-15	Bristol-Myers Squibb Company	Carbazole compounds useful as bromodomain inhibitors
CA2902225A1 (en) *	2013-02-28	2014-09-04	Washington University	Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors
WO2014164780A1 (en)	2013-03-11	2014-10-09	Abbvie Inc.	Fused tetracyclic bromodomain inhibitors
US9050346B2 (en)	2013-03-11	2015-06-09	Abbvie Inc.	Bromodomain inhibitors
WO2014159837A1 (en)	2013-03-14	2014-10-02	Convergene Llc	Methods and compositions for inhibition of bromodomain-containing proteins
CN105189515B (zh) *	2013-03-14	2018-07-03	葛兰素史克知识产权第二有限公司	作为溴结构域抑制剂的呋喃并吡啶类
US9714946B2 (en)	2013-03-14	2017-07-25	Dana-Farber Cancer Institute, Inc.	Bromodomain binding reagents and uses thereof
SG10201707487VA (en)	2013-03-15	2017-10-30	Incyte Corp	Tricyclic heterocycles as bet protein inhibitors
EP2792355A1 (en)	2013-04-17	2014-10-22	Albert-Ludwigs-Universität Freiburg	Compounds for use as bromodomain inhibitors
JP6388915B2 (ja)	2013-04-26	2018-09-12	ベイジーン，リミテッド	置換５−（３，５−ジメチルイソオキサゾール−４−イル）インドリン−２−オン
SG10201710705UA (en)	2013-06-21	2018-02-27	Zenith Epigenetics Ltd	Novel bicyclic bromodomain inhibitors
WO2015004534A2 (en)	2013-06-21	2015-01-15	Zenith Epigenetics Corp.	Novel substituted bicyclic compounds as bromodomain inhibitors
AR096758A1 (es) *	2013-06-28	2016-02-03	Abbvie Inc	Inhibidores cristalinos de bromodominios
JP2016523964A (ja)	2013-07-08	2016-08-12	インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅＨｏｌｄｉｎｇｓＣｏｒｐｏｒａｔｉｏｎ	Ｂｅｔタンパク質阻害剤としての三環式複素環
KR20160034379A (ko)	2013-07-25	2016-03-29	다나-파버 캔서 인스티튜트 인크.	전사 인자의 억제제 및 그의 용도
EP3027604B1 (en)	2013-07-31	2019-02-20	Zenith Epigenetics Ltd.	Novel quinazolinones as bromodomain inhibitors
US9428513B2 (en)	2013-11-07	2016-08-30	Boehringer Ingelheim International Gmbh	Triazolopyrazine
MX2016005980A (es)	2013-11-08	2016-12-09	Dana Farber Cancer Inst Inc	Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal.
WO2015081203A1 (en)	2013-11-26	2015-06-04	Incyte Corporation	Bicyclic heterocycles as bet protein inhibitors
WO2015081189A1 (en)	2013-11-26	2015-06-04	Incyte Corporation	Bicyclic heterocycles as bet protein inhibitors
GB201320994D0 (en) *	2013-11-28	2014-01-15	Univ Dundee	Enzyme function probes
US9309246B2 (en)	2013-12-19	2016-04-12	Incyte Corporation	Tricyclic heterocycles as BET protein inhibitors
CN106029653A (zh)	2014-01-31	2016-10-12	达纳-法伯癌症研究所股份有限公司	二氨基嘧啶苯砜衍生物及其用途
US10793571B2 (en)	2014-01-31	2020-10-06	Dana-Farber Cancer Institute, Inc.	Uses of diazepane derivatives
JP2017504650A (ja)	2014-01-31	2017-02-09	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	ジアゼパン誘導体およびその使用
CN106459056A (zh) *	2014-02-10	2017-02-22	康塞特医药品公司	经取代的三唑苯二氮卓
EP3104845A4 (en) *	2014-02-10	2017-09-27	Salk Institute for Biological Studies	Increasing storage of vitamin a, vitamin d and/or lipids
WO2015121230A1 (de) *	2014-02-14	2015-08-20	Bayer Pharma Aktiengesellschaft	9-substituierte 2,3-benzodiazepine
MX2016011160A (es)	2014-02-28	2017-04-27	Tensha Therapeutics Inc	Tratamiento de afecciones asociadas con la hiperinsulinemia.
WO2015156601A1 (en)	2014-04-09	2015-10-15	Kainos Medicine, Inc.	Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer
PT3134403T (pt)	2014-04-23	2020-05-18	Incyte Corp	1h-pirrolo[2,3-c]piridin-7(6h)-onas e pirazolo[3,4-c]piridin-7(6h)-onas como inibidores das proteínas bet
WO2015195862A1 (en)	2014-06-20	2015-12-23	Constellation Pharmaceuticals, Inc.	Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4s5-e]azepin-4-yl)acetamide
NO2719005T3 (da)	2014-07-28	2018-01-20
AU2015295405B2 (en) *	2014-08-01	2020-04-09	Nuevolution A/S	Compounds active towards bromodomains
EP3177626A4 (en)	2014-08-08	2017-12-27	Dana Farber Cancer Institute, Inc.	Diazepane derivatives and uses thereof
WO2016022970A1 (en)	2014-08-08	2016-02-11	Dana-Farber Cancer Institute, Inc.	Dihydropteridinone derivatives and uses thereof
JP6599979B2 (ja)	2014-09-15	2019-10-30	インサイト・コーポレイション	Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
EP3201199A1 (en)	2014-10-02	2017-08-09	Glaxosmithkline Intellectual Property (No. 2) Limited	Compound
SG11201703414VA (en)	2014-10-27	2017-05-30	Tensha Therapeutics Inc	Bromodomain inhibitors
WO2016087936A1 (en)	2014-12-01	2016-06-09	Zenith Epigenetics Corp.	Substituted pyridinones as bromodomain inhibitors
CA2966303A1 (en)	2014-12-01	2016-06-09	Zenith Epigenetics Ltd.	Substituted pyridines as bromodomain inhibitors
JP2017537166A (ja) *	2014-12-05	2017-12-14	エイチリーモフィットキャンサーセンターアンドリサーチインスティテュートインコーポレイテッド	癌免疫療法におけるアジュバントとしてのブロモドメイン阻害剤
CA2966449A1 (en)	2014-12-11	2016-06-16	Zenith Epigenetics Ltd.	Substituted heterocycles as bromodomain inhibitors
EP3233846A4 (en)	2014-12-17	2018-07-18	Zenith Epigenetics Ltd.	Inhibitors of bromodomains
EP3253756B1 (en)	2015-02-03	2021-09-22	Trillium Therapeutics Inc.	Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins
GB201504694D0 (en)	2015-03-19	2015-05-06	Glaxosmithkline Ip Dev Ltd	Covalent conjugates
WO2016201370A1 (en)	2015-06-12	2016-12-15	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
KR20180035785A (ko)	2015-06-26	2018-04-06	텐샤 세러퓨틱스 인코포레이티드	Nut 중간선 암종의 치료
JP6765622B2 (ja)	2015-07-17	2020-10-07	日本光電工業株式会社	救命支援装置
UA123946C2 (uk)	2015-09-11	2021-06-30	Дана-Фарбер Кенсер Інстітьют, Інк.	Ацетамідтієнотриазолодіазепіни й шляхи їх застосування
SG10202007090UA (en)	2015-09-11	2020-08-28	Dana Farber Cancer Inst Inc	Cyano thienotriazolodiazepines and uses thereof
KR20180081507A (ko) *	2015-10-02	2018-07-16	다나-파버 캔서 인스티튜트 인크.	브로모도메인 저해제와 관문 차단의 조합 요법
AR106520A1 (es)	2015-10-29	2018-01-24	Incyte Corp	Forma sólida amorfa de un inhibidor de proteína bet
JP7385356B2 (ja)	2015-11-25	2023-11-22	ダナ－ファーバーキャンサーインスティテュート，インコーポレイテッド	二価ブロモドメインインヒビターおよびそれらの使用
KR102250415B1 (ko)	2016-04-15	2021-05-11	애브비 인코포레이티드	브로모도메인 저해제
PE20240236A1 (es)	2016-06-20	2024-02-16	Incyte Corp	Formas solidas cristalinas de un inhibidor de bet
US10918647B2 (en)	2016-07-26	2021-02-16	University Of Southern California	Selective bromodomain inhibition of fungal Bdf1
CA3045855A1 (en)	2016-11-10	2018-05-17	Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.	Nitrogenous macrocyclic compound, preparation method therefor, pharmaceutical composition and application thereof
US11497756B2 (en)	2017-09-12	2022-11-15	Sumitomo Pharma Oncology, Inc.	Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
CN107759607B (zh) *	2017-11-29	2019-08-23	上海万巷制药有限公司	具有抗肿瘤活性的三氮唑并二氮卓化合物及其制备方法
WO2020117988A1 (en)	2018-12-04	2020-06-11	Tolero Pharmaceuticals, Inc.	Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
JP2022525149A (ja)	2019-03-20	2022-05-11	スミトモダイニッポンファーマオンコロジー，インコーポレイテッド	ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
GB201905721D0 (en)	2019-04-24	2019-06-05	Univ Dundee	Compounds
WO2021175432A1 (en)	2020-03-04	2021-09-10	Boehringer Ingelheim International Gmbh	Method for administration of an anti cancer agent
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
CR20220658A (es)	2020-06-23	2023-04-26	Genentech Inc	Compuestos macrocíclicos y métodos de uso de los mismos
GB202016977D0 (en)	2020-10-26	2020-12-09	In4Derm Ltd	Compounds
JP2023538405A (ja)	2020-12-01	2023-09-07	成都苑▲東▼生物制▲薬▼股▲ふん▼有限公司	新規ｎ－複素環ｂｅｔブロモドメイン阻害剤、その調製方法及び医薬応用
MX2024000238A (es)	2021-06-29	2024-01-30	Tay Therapeutics Ltd	Derivados de pirrolopiridona utiles en el tratamiento del cancer.
AU2023255396A1 (en)	2022-04-19	2024-10-24	Nuevolution A/S	Compounds active towards bromodomains
WO2024018423A1 (en)	2022-07-21	2024-01-25	Tay Therapeutics Limited	Pyrroles and imidazoles as bet protein inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3610848A1 (de) *	1986-04-01	1987-10-15	Boehringer Ingelheim Kg	Neue 1,4-diazepine
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
CA2120939A1 (en)	1991-10-11	1993-04-15	Tetsuya Tahara	Therapeutic agent for osteoporosis and diazepine compound
JPH06128257A (ja)	1992-10-13	1994-05-10	Yoshitomi Pharmaceut Ind Ltd	ピリドジアゼピン化合物
AU686715B2 (en)	1993-11-22	1998-02-12	Merck & Co., Inc.	Tricyclic benzodiazepinyl amide derivatives as amtiarrhythmics
IT1285567B1 (it)	1996-02-21	1998-06-18	Alfa Chem Ital	Nuovo processo per la sintesi del nabumetone
EP0934940A1 (en) *	1996-06-12	1999-08-11	Japan Tobacco Inc.	Cytokine production inhibitors, triazepine compounds, and intermediates thereof
DK0989131T3 (da)	1996-09-13	2003-03-03	Mitsubishi Pharma Corp	Thienotriazolodiazepinforbindelser og deres medicinske anvendelse
JPH11228576A (ja) *	1997-12-10	1999-08-24	Japan Tobacco Inc	アポトーシス抑制剤
WO2005044354A1 (en)	2003-11-03	2005-05-19	Glaxo Group Limited	A fluid dispensing device
CN1739788A (zh)	2004-03-31	2006-03-01	新加坡国立大学	Trip－br功能的调节和治疗增殖性紊乱的方法
GB0420970D0 (en)	2004-09-21	2004-10-20	Smithkline Beecham Corp	Novel triazoloquinoline compounds
US8044042B2 (en)	2005-05-30	2011-10-25	Mitsubishi Tanabe Pharma Corporation	Thienotriazolodiazepine compound and medicinal use thereof
JP2008156311A (ja)	2006-12-26	2008-07-10	Institute Of Physical & Chemical Research	Ｂｒｄ２ブロモドメイン結合剤
CN101910182B (zh)	2007-12-28	2013-07-17	田边三菱制药株式会社	抗癌剂
GB0919431D0 (en)	2009-11-05	2009-12-23	Glaxosmithkline Llc	Novel compounds

2010
- 2010-08-06 DK DK10740654.8T patent/DK2496580T3/da active
- 2010-08-06 PE PE2012000614A patent/PE20121181A1/es not_active Application Discontinuation
- 2010-08-06 PT PT107406548T patent/PT2496580E/pt unknown
- 2010-08-06 ME MEP-2016-53A patent/ME02360B/me unknown
- 2010-08-06 US US13/505,039 patent/US9023842B2/en active Active
- 2010-08-06 JP JP2012537329A patent/JP5524343B2/ja active Active
- 2010-08-06 CA CA2779355A patent/CA2779355C/en not_active Expired - Fee Related
- 2010-08-06 EP EP10740654.8A patent/EP2496580B1/en active Active
- 2010-08-06 MX MX2012005295A patent/MX2012005295A/es active IP Right Grant
- 2010-08-06 EA EA201290183A patent/EA020390B1/ru not_active IP Right Cessation
- 2010-08-06 MY MYPI2012001967A patent/MY160456A/en unknown
- 2010-08-06 KR KR1020127014637A patent/KR101424989B1/ko active IP Right Grant
- 2010-08-06 BR BR112012010706A patent/BR112012010706A2/pt active Search and Examination
- 2010-08-06 ES ES10740654.8T patent/ES2446647T3/es active Active
- 2010-08-06 PL PL13192666T patent/PL2722334T3/pl unknown
- 2010-08-06 ES ES13192666.9T patent/ES2563057T3/es active Active
- 2010-08-06 AU AU2010314395A patent/AU2010314395B2/en not_active Ceased
- 2010-08-06 EP EP16150637.3A patent/EP3037423B1/en active Active
- 2010-08-06 RS RS20140088A patent/RS53179B/en unknown
- 2010-08-06 RS RS20160102A patent/RS54592B1/en unknown
- 2010-08-06 SI SI201031117T patent/SI2722334T1/sl unknown
- 2010-08-06 WO PCT/EP2010/061518 patent/WO2011054553A1/en active Application Filing
- 2010-08-06 PL PL10740654T patent/PL2496580T3/pl unknown
- 2010-08-06 SI SI201030514T patent/SI2496580T1/sl unknown
- 2010-08-06 HU HUE13192666A patent/HUE026421T2/en unknown
- 2010-08-06 DK DK13192666.9T patent/DK2722334T3/da active
- 2010-08-06 PT PT131926669T patent/PT2722334E/pt unknown
- 2010-08-06 ES ES16150637.3T patent/ES2652304T3/es active Active
- 2010-08-06 EP EP13192666.9A patent/EP2722334B1/en active Active
- 2010-08-06 PH PH1/2012/500894A patent/PH12012500894A1/en unknown
- 2010-08-06 NZ NZ599258A patent/NZ599258A/en not_active IP Right Cessation
- 2010-08-06 CN CN201080050285.XA patent/CN102762569B/zh not_active Expired - Fee Related
2012
- 2012-04-05 IL IL219090A patent/IL219090A0/en unknown
- 2012-04-18 DO DO2012000114A patent/DOP2012000114A/es unknown
- 2012-05-04 CL CL2012001178A patent/CL2012001178A1/es unknown
- 2012-05-10 CO CO12077201A patent/CO6540003A2/es unknown
- 2012-05-28 CR CR20120283A patent/CR20120283A/es unknown
- 2012-06-04 MA MA34934A patent/MA33803B1/fr unknown
2013
- 2013-02-21 HK HK13102225.8A patent/HK1175458A1/xx not_active IP Right Cessation
- 2013-02-21 HK HK14104251.0A patent/HK1191012A1/zh not_active IP Right Cessation
2014
- 2014-02-05 HR HRP20140107AT patent/HRP20140107T1/hr unknown
- 2014-02-18 CY CY20141100124T patent/CY1114988T1/el unknown
- 2014-02-20 SM SM201400024T patent/SMT201400024B/xx unknown
- 2014-11-30 IL IL235983A patent/IL235983B/en active IP Right Grant
2015
- 2015-04-13 US US14/684,659 patent/US20150210706A1/en not_active Abandoned
2016
- 2016-02-03 HR HRP20160119TT patent/HRP20160119T1/hr unknown
- 2016-03-01 CY CY20161100172T patent/CY1117479T1/el unknown
- 2016-03-22 SM SM201600081T patent/SMT201600081B/xx unknown
- 2016-07-13 HK HK16108220.7A patent/HK1220188A1/zh unknown
2017
- 2017-01-20 US US15/410,874 patent/US20170197972A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CL2012001178A1 (es)	2012-10-05
CA2779355C (en)	2018-01-16
HRP20140107T1 (hr)	2014-04-25
PT2722334E (pt)	2016-03-11
CR20120283A (es)	2012-08-14
ME02360B (me)	2016-06-20
ES2563057T3 (es)	2016-03-10
SI2722334T1 (sl)	2016-03-31
RS53179B (en)	2014-06-30
IL235983B (en)	2018-01-31
IL219090A0 (en)	2012-06-28
PE20121181A1 (es)	2012-09-13
PT2496580E (pt)	2014-02-21
BR112012010706A2 (pt)	2016-03-29
RS54592B1 (en)	2016-08-31
EP2496580B1 (en)	2013-12-11
DOP2012000114A (es)	2012-08-15
KR20120099250A (ko)	2012-09-07
EP2722334A1 (en)	2014-04-23
KR101424989B1 (ko)	2014-07-31
HUE026421T2 (en)	2016-05-30
CY1117479T1 (el)	2017-04-26
WO2011054553A1 (en)	2011-05-12
PH12012500894A1 (en)	2022-03-09
CN102762569B (zh)	2015-04-01
MA33803B1 (fr)	2012-12-03
US20150210706A1 (en)	2015-07-30
EP3037423A1 (en)	2016-06-29
PL2496580T3 (pl)	2014-06-30
EP3037423B1 (en)	2017-09-20
ES2446647T3 (es)	2014-03-10
DK2722334T3 (da)	2016-03-07
IL235983A0 (en)	2015-01-29
HK1175458A1 (en)	2013-07-05
US20120220573A1 (en)	2012-08-30
AU2010314395A1 (en)	2012-05-24
JP5524343B2 (ja)	2014-06-18
MX2012005295A (es)	2012-06-19
PL2722334T3 (pl)	2016-06-30
MY160456A (en)	2017-03-15
US9023842B2 (en)	2015-05-05
EP2496580A1 (en)	2012-09-12
JP2013510107A (ja)	2013-03-21
CN102762569A (zh)	2012-10-31
US20170197972A1 (en)	2017-07-13
SMT201600081B (it)	2016-04-29
EA201290183A1 (ru)	2012-12-28
NZ599258A (en)	2014-05-30
AU2010314395B2 (en)	2015-04-09
EP2722334B1 (en)	2016-01-13
HK1220188A1 (zh)	2017-04-28
HK1191012A1 (zh)	2014-07-18
SI2496580T1 (sl)	2014-02-28
HRP20160119T1 (hr)	2016-02-26
SMT201400024B (it)	2014-07-07
EA020390B1 (ru)	2014-10-30
CY1114988T1 (el)	2016-12-14
ES2652304T3 (es)	2018-02-01
CA2779355A1 (en)	2011-05-12
CO6540003A2 (es)	2012-10-16

Publication	Publication Date	Title
DK2496580T3 (da)	2014-02-24	Benzodiazepinbromdomænehæmmer
CY2020024I1 (el)	2020-11-25	Αναστολεiς βητα-λακταμασων
LTPA2020505I1 (lt)	2020-04-10	Nauji tricikliniai junginiai
SMT201600104B (it)	2016-04-29	Inibitore di bromodominio benzodiazepinico
CY2017016I1 (el)	2017-07-12	Αναστολεις πρωτεασωματος
DK2278945T3 (da)	2014-03-31	Rektal drænindretning
BRPI1008749A2 (pt)	2015-08-25	Derivados de benzodiazepina
BRPI0915374A2 (pt)	2015-08-04	Novos compostos tricíclicos
BRPI0908115A2 (pt)	2015-10-06	torneira
BRPI1009315A2 (pt)	2016-03-08	agentes anti-inflamatórios
DK2246336T3 (da)	2020-07-20	Fibroseinhibitor
BRPI0918564A2 (pt)	2015-12-01	inibidores
EP2495242A4 (en)	2013-04-10	NEW VEGETABLE DISADVANTAGE
EP2413941A4 (en)	2012-10-10	INHIBITORS OF THE RENIN
BRPI0923550A2 (pt)	2016-01-26	penico
BRPI0914538A2 (pt)	2015-12-15	derivados tricíclicos substituídos
EP2177529A4 (en)	2011-04-20	NEW SECRETASE HEMMER
ATE522533T1 (de)	2011-09-15	Pyrazolopyrimidinonkinaseinhibitor
DE102009039671A8 (de)	2011-06-01	Sanitärarmatur
EP2273877A4 (en)	2011-08-31	CYCLOBUTYLSULFONES AS NOTCH-SAVING GAMMA-SECRETASE INHIBITORS
BRPI1008993A2 (pt)	2016-03-22	marcadores fecais
DK2101000T3 (da)	2014-09-22	Hydrant
ES1071763Y (es)	2010-07-01	Inodoro autoaspirable
UA20124S (uk)	2010-03-10	Комод
UA20121S (uk)	2010-03-10	Комод